RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Researchers in China Acknowledge TLD1433 Safety and EfficacyRumpl3StiltSkin wrote ScienceFirst wrote: Just the molecule is not enough for big pharmas.
The will need the laser, optical cage, TLD-3200, so any hostile takeover would not work, as they have no expertise. Roger has probably thought of all these tiny details.
They will definetly need the Laser and Dosimetry expertise from TLT on NMIBC. I think this is a perfect opportunity for TLT and the right Pharma. TLT can do a JV on just THIS indication. Keeping 1433/Rutherin for themselves for future solid tumors. :-) The question is how much $$$ can TLT expect ?? do they get the Laser/Dosimetry sales only? Or maybe also a 10% royalty on 1433? Any upfront money $$$ for research? Or just Money in general? Far too many options because of future successes that should be part of any discussions in all avenues of plans of business growth. This you can bet has been well addressed by the company and I can also understand that they wouldn't want to discuss this in an open forum as that could tip their hand to their future partners advantage. I also think in my personal opinion that even an offer of less than $25.00 is low ball.